Professor Paul Loadman,Professor
Information about Professor Paul Loadman at the University of Bradford.
- School of Pharmacy & Medical Sciences
(Faculty of Life Sciences) - Email:
- p.m.loadman@bradford.ac.uk
- Telephone:
- +44 1274 233228
Biography
Pharmacokinetics and tumour drug metabolism of anti-cancer drugsProfessor Paul Loadman heads the drugmetabolism team at the Institute of Cancer Therapeutics, University of Bradfordand has >20years experience studyingthe pharmacokinetics and metabolism of anti-cancer drugs. The team in Bradford havestudied a wide range of clinically available and novel small moleculesincluding antimetabolites, platinating and alkylating agents, peptides andantivascular compounds. Prof Loadman is actively involved in the design,analysis and reporting of pre-clinical and clinical pharmacokinetic studies andacts as a pharmacokinetic and drug metabolism consultant for numerouspharmaceutical and biotechnology companies.Togetherwith Prof Twelves (ClinicalDirector,) the DMPK team have established a Quality Management System withinthe ICT which has enabled a strong involvement in the pharmacokineticmonitoring of small molecules in major clinical trials. Other major clinical collaborationsinclude with Professor Mark Hull at the University of Leeds (The seAFOod Polyp Prevention Trial, www.seafood-trial.co.uk) where the laboratory in Bradford are analyzing a series of bioactive lipidmediators such as ω-3 PUFAs, resolvin E1 and PGE-M in plasma, urine,erythrocytes and rectal mucosa in order to gain insights into the mechanism ofaction of EPA and aspirin.
Research
- Pharmacokinetics and tumour drug metabolism of anti cancer drugs
- Matrix metalloproteinases as targets for tumour-selective delivery of anticancer therapeutics
- Drug delivery and prodrug design
- Novel advances in analytical techniques. HPLC, GC, CE and LC/MS/MS
- Drug interactions both in vitro and in vivo
Professional activities
Information about education, employment and areas of particular interest for Professor Paul Loadman is as follows:
Education
- University of Bradford - PhD
Publications
There are 134 publications involving or that are attributed to Professor Paul Loadman. They are listed as:
- book chapter (4)
- peer reviewed journal (125)
- reviews (5)
Book Chapter
| Title | Year | Publication name | Journal | Volume | Pages | Authors | Editors | ISSN | Publisher | DOI | Location |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Development of tumour selective and endoprotease-activated anticancer therapeutics. | 2008 | Gill, Jason H.; Loadman, Paul M. | |||||||||
| Practical aspects of pharmacokinetics and pharmacodynamics | 2015 | Loadman, Paul M. | |||||||||
| Wnt Signaling as a Therapeutic Target in Cancer and Metastasis | 2017 | Morgan, Richard; Ankrah, R.; El-Tanani, S.; Patterson, Laurence H.; Loadman, Paul M.; Rudland, P.S.; El-Tanani, Mohamed | |||||||||
| Development of tumour-selective and endoprotease-activated anticancer therapeutics | 2008 | The Cancer Degradome: Proteases and Cancer Biology | The Cancer Degradome: Proteases and Cancer Biology | 853 - 876 | Gill J.;Loadman P. | 9780387690568 | 10.1007/978-0-387-69057-5_40 |
Peer Reviewed Journal
| Title | Year | Publication name | Journal | Volume | Pages | Authors | Editors | ISSN | Publisher | DOI | Location |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cytochrome P450 1B1 (CYP1B1) is over-expressed in human colon adeno-carcinomas relative to normal colon: Implications for drug development. | 2003 | Gibson, Paul; Gill, Jason H.; Khan, Parveen A.; Seargent, Jill M.; Martin, Sandie W.; Batman, Philip A.; Griffith, John; Bradley, C.; Double, John A.; Bibby, Michael C.; Loadman, Paul M. | |||||||||
| MMP-10 is overexpressed, proteolytically active and a potential target for therapeutic intervention in human lung carcinomas | 2004 | Gill, Jason H.; Kirwan, Ian G.; Seargent, Jill M.; Martin, Sandie W.; Tijani, S.; Anikin, V.A.; Mearns, A.J.; Bibby, Michael C.; Anthoney, Alan; Loadman, Paul M. | |||||||||
| Phase I/II Pilot Study of Intravesical Apaziquone (EO9) for Superficial Bladder Cancer | 2006 | Puri, Rajiv; Palit, V.; Loadman, Paul M.; Flannigan, G. Michael; Shah, T.K.; Choudry, G.A.; Basu, Saurajyoti; Double, John A.; Lenaz, G.; Chawla, S.; Beer, M.; Kalken, C.V.; de Boer, R.; Beijnen, J.H.; Twelves, Christopher J.; Phillips, Roger M. | |||||||||
| Membrane Type MMPs Show Differential Expression in Non-Small Cell Lung Cancer (NSCLC) Compared to Normal Lung; Correlation of MMP-14 mRNA Expression and Proteolytic Activity. | 2007 | Atkinson, Jennifer M.; Gill, Jason H.; Loadman, Paul M.; Martin, Sandie W.; Pennington, J.; Anikin, V.A.; Mearns, A.J.; Edwards, D.R. | |||||||||
| The use of pharmacokinetic and pharmacodynamic end points to determine the dose of AQ4N, a novel hypoxic cell cytotoxin, given with fractionated radiotherapy in a phase I study. | 2009 | Steward, W.P.; Middleton, M.; Benghiat, A.; Loadman, Paul M.; Hayward, C.; Walter, S.; Ford, S.; Halbert, G.; Patterson, Laurence H.; Talbot, D. | |||||||||
| Pharmacological and biological evaluation of a series of substituted 1,4 naphthoquinone bioreductive drugs. | 2004 | Phillips, Roger M.; Loadman, Paul M.; Maitland, Derek J.; Shnyder, Steven D.; Jaffar, M.; Steans, Gillian; Cooper, Patricia A.; Race, Amanda D.; Patterson, A.V.; Stratford, I.J. | |||||||||
| Preclinical pharmacology of the pyrrolobenzodiazepine (PBD) monomer DRH-417 (NSC 709119). | 2007 | Burger, A.M.; Loadman, Paul M.; Thurston, D.E.; Schultz, R.; Fiebig, H.H.; Bibby, Michael C. | |||||||||
| Preliminary pharmacokinetic and bioanalytical studies of SJG-136 (NSC 694501), a sequence-selective pyrrolobenzodiazepine dimer DNA-cross-linking agent. | 2004 | Wilkinson, Gary P.; Taylor, James P.; Shnyder, Steven D.; Loadman, Paul M.; Cooper, Patricia A.; Howard, P.W.; Thurston, D.E.; Jenkins, Terence C. | |||||||||
| Hypoxia-selective targeting by the bioreductive prodrug AQ4N in patients with solid tumors: results of a phase 1 study | 2008 | Albertella, M.R.; Loadman, Paul M.; Jones, P.H.; Phillips, Roger M.; Rampling, R.; Burnet, N.; Alcock, C.; Anthoney, Alan; Vjaters, E.; Dunk, C.R.; Harris, P.A.; Wong, A.; Lalani, A.S.; Twelves, Christopher J. | |||||||||
| Fluorescent 7-Diethylaminocoumarin Pyrrolobenzodiazepine conjugates: Synthesis, DNA-Interaction, Cytotoxicity and Differential Cellular Localization. | 2008 | Wells, G.; Suggitt, Marie; Coffils, M.; Baig, M.A.H.; Howard, P.W.; Loadman, Paul M.; Hartley, J.A.; Jenkins, Terence C.; Thurston, D.E. | |||||||||
| Chemical synthesis and biological evaluation of a NAD(P)H:quinone oxidoreductase-1-targeted tripartite quinone drug delivery system | 2007 | Volpato, Milène; Abou-Zeid, N.; Tanner, R.W.; Glassbrook, L.T.; Taylor, James P.; Stratford, I.J.; Loadman, Paul M.; Jaffar, M.; Phillips, Roger M. | |||||||||
| Method development for protein profiling in biological tissues by matrix-assisted laser desorption/ionisation mass spectrometry imaging. | 2008 | Djidja, M-C.; Carolan, V.A.; Loadman, Paul M.; Clench, M.R. | |||||||||
| A mathematical model of doxorubicin penetration through multicellular layers, | 2009 | Evans, C.J.; Phillips, Roger M.; Jones, P.F.; Loadman, Paul M.; Sleeman, B.D.; Twelves, Christopher J.; Smye, S.W. | |||||||||
| Detergent addition to trypsin digest and Ion Mobility Separation prior to MS/MS improves peptide yield and Protein Identification for in situ Proteomic Investigation of Frozen and FFPE Adenocarcinoma tissue sections. | 2009 | Djidja, M-C.; Francese, S.; Loadman, Paul M.; Sutton, Chris W.; Scriven, P.; Claude, E.; Snel, M.F.; Franck, J.; Salzet, M.; Clench, M.R. | |||||||||
| In vivo activation of the hypoxia-targeted cytotoxin AQ4N in human tumor xenograft. | 2009 | Williams, K.J.; Albertella, M.R.; Fitzpatrick, B.; Loadman, Paul M.; Shnyder, Steven D.; Chinje, E.C.; Telfer, B.A.; Dunk, C.R.; Harris, P.A.; Stratford, I.J. | |||||||||
| Evaluation of the safety of C-1311 (SYMADEX) administered in a phase 1 dose escalation trial as a weekly infusion for 3 consecutive weeks in patients with advanced solid tumours. | 2010 | Isambert, N.; Campone, M.; Bourbouloux, E.; Drouin, M.; Major, A.; Yin, W.; Loadman, Paul M.; Capizzi, R.; Grieshaber, C.; Fumoleau, P. | |||||||||
| Development of a novel tumor-targeted vascular disrupting agent activated by Membrane-type Matrix Metalloproteinases (MT-MMPs) | 2010 | Atkinson, Jennifer M.; Falconer, Robert A.; Edwards, D.R.; Pennington, C.J.; Siller, Catherine S.; Shnyder, Steven D.; Bibby, Michael C.; Patterson, Laurence H.; Loadman, Paul M.; Gill, Jason H. | |||||||||
| Effect of eicosapentaenoic acid on E-type prostaglandin synthesis and EP4 receptor signalling in human colorectal cancer cells | 2010 | Hawcroft, G.; Loadman, Paul M.; Belluzzi, A.; Hull, M.A. | |||||||||
| Modification of the duocarmycin pharmacophore enables CYP1A1 targeting for biological activity | 2011 | Pors, Klaus; Loadman, Paul M.; Shnyder, Steven D.; Sutherland, Mark H.; Sheldrake, Helen M.; Guino, M.; Kiakos, K.; Hartley, J.A.; Searcey, M.; Patterson, Laurence H. | |||||||||
| Phase I study of sequence-selective minor groove DNA binding agent SJG-136 in patients with advanced solid tumors | 2009 | Hochhauser, D.; Meyer, T.; Spanswick, V.J.; Wu, J.; Clingen, P.H.; Loadman, Paul M.; Cobb, M.; Gumbrell, L.; Begent, R.H.; Hartley, J.A.; Jodrell, D. | |||||||||
| Immunohistochemical analysis of NAD(P)H:quinone oxidoreductase and NADPH cytochrome P450 reductase in human superficial bladder tumours: Relationship between tumour enzymology and clinical outcome following intravesical mitomycin C therapy | 2004 | Basu, Saurajyoti; Brown, John E.; Flannigan, G. Michael; Gill, Jason H.; Loadman, Paul M.; Naylor, Brian; Scally, Andy J.; Seargent, Jill M.; Shah, Tariq K.; Puri, Rajiv; Phillips, Roger M.; Martin, Sandie W. | |||||||||
| Antitumor activity of a duocarmycin analogue rationalized to be metabolically activated by cytochrome P450 1A1 in human transitional cell carcinoma of the bladder | 2013 | Sutherland, Mark H.; Gill, Jason H.; Loadman, Paul M.; Laye, Jonathan P.; Sheldrake, Helen M.; Illingworth, Nicola A.; Alandas, Mohammed N.; Cooper, Patricia A.; Searcey, M.; Pors, Klaus; Shnyder, Steven D.; Patterson, Laurence H. | |||||||||
| Colon cancer-specific cytochrome P450 2W1 converts duocarmycin analogues into potent tumor cytotoxins | 2013 | Travica, S.; Pors, Klaus; Loadman, Paul M.; Shnyder, Steven D.; Johansson, I.; Alandas, Mohammed N.; Sheldrake, Helen M.; Mkrtchian, S.; Patterson, Laurence H.; Ingelman-Sundberg, M. | |||||||||
| NAD(P)H:Quinone oxidoreductase-1 C609T polymorphism analysis in human superficial bladder cancers: relationship of genotype status to NQO1 phenotype and clinical response to Mitomycin C. | 2004 | Basu, Saurajyoti; Brown, John E.; Flannigan, G. Michael; Gill, Jason H.; Loadman, Paul M.; Martin, Sandie W.; Naylor, Brian; Puri, Rajiv; Scally, Andy J.; Seargent, Jill M.; Shah, Tariq K.; Phillips, Roger M. | |||||||||
| Thin-layer chromatography/matrix-assisted laser desorption/ionisation mass spectrometry and matrix-assisted laser desorption/ionisation mass spectrometry imaging for the analysis of phospholipids in LS174T colorectal adenocarcinoma xenografts treated with the vascular disrupting agent DMXAA | 2015 | Rapid Communications In Mass Spectrometry | 29 | 1288 - 1296 | Batubara, A.; Carolan, V.A.; Loadman, Paul M.; Sutton, Chris W.; Shnyder, Steven D.; Clench, M.R. | doi.org/10.1002/rcm.7223 | |||||
| Polysialic acid sustains cancer cell survival and migratory capacity in a hypoxic environment | 2016 | Scientific Reports | 6 | 33026 | Elkashef, Sara M.; Allison, Simon J.; Sadiq, Maria; Basheer, Haneen A.; Ribeiro Morais, Goreti; Loadman, Paul M.; Pors, Klaus; Falconer, Robert A. | 10.1038/srep33026 | |||||
| Tumor-Targeted Prodrug ICT2588 Demonstrates Therapeutic Activity Against Solid Tumors and Reduced Potential For Cardiovascular Toxicity | 2014 | Molecular Cancer Therapeutics | 11 | 1294 - 1300 | Gill, Jason H.; Loadman, Paul M.; Shnyder, Steven D.; Cooper, Patricia A.; Atkinson, Jennifer M.; Ribeiro Morais, Goreti; Patterson, Laurence H.; Falconer, Robert A. | 10.1021/mp400760b | |||||
| Development of Novel Tumor-Targeted Theranostic Nanoparticles Activated by Membrane-Type Matrix Metalloproteinases for Combined Cancer Magnetic Resonance Imaging and Therapy | 2014 | Small | 10 | 565 - 575 | Ansari, C.; Tikhomirov, G.A.; Hong, S.H.; Falconer, Robert A.; Loadman, Paul M.; Gill, Jason H.; Castaneda, R.; Hazard, F.K.; Tong, L.; Lenkov, O.D.; Felsher, D.W.; Rao, J.; Daldrup-Link, H.E. | 10.1002/smll.201301456 | |||||
| Pharmacological Inhibition of polysialyltransferase ST8SiaII Modulates Tumour Cell Migration | 2013 | PLoS ONE | 8 | e73366 | Al-Saraireh, Yousef M.J.; Sutherland, Mark H.; Springett, Bradley R.; Freiberger, F.; Ribeiro Morais, Goreti; Loadman, Paul M.; Errington, R.J.; Smith, P.J.; Fukuda, M.; Gerardy-Schahn, R.; Patterson, Laurence H.; Shnyder, Steven D.; Falconer, Robert A. | 10.1371/journal.pone.0073366 | |||||
| An optimised assay for quantitative, high-throughput analysis of polysialyltransferase activity | 2016 | ANALYST (PRINT) | 141 | 5849 - 5856 | Elkashef, Sara M.; Sutherland, Mark H.; Patterson, Laurence H.; Loadman, Paul M.; Falconer, Robert A. | 10.1039/c6an01073c | |||||
| Identification of Stage-Specific Breast Markers using Quantitative Proteomics | 2013 | Shaheed, Sadr-ul; Rustogi, Nitin; Scally, Andy J.; Wilson, J.; Thygesen, H.; Loizidou, M.A.; Hadjisavvas, A.; Hanby, A.; Speirs, V.; Loadman, Paul M.; Linforth, R.; Kyriacou, K.; Sutton, Chris W. | |||||||||
| Targeting of Hypoxia in AQ4N-treated Tumour Xenografts by MALDI-Ion Mobility Separation-Mass Spectrometry Imaging | 2013 | Djidja, M-C.; Francese, S.; Claude, E.; Loadman, Paul M.; Sutton, Chris W.; Shnyder, Steven D.; Cooper, Patricia A.; Patterson, Laurence H.; Carolan, V.A.; Clench, M.R. | |||||||||
| A randomised controlled trial of eicosapentaenoic acid and/or aspirin for colorectal adenoma (or polyp) prevention during colonoscopic surveillance in the NHS Bowel Cancer Screening Programme: The seAFOod (Systematic Evaluation of Aspirin and Fish Oil) Polyp Prevention Trial | 2013 | Hull, M.A.; Sandell, A.C.; Montgomery, A.A.; Logan, R.F.A.; Clifford, G.M.; Rees, C.J.; Loadman, Paul M.; Whitham, D. | |||||||||
| Probing cytochrome P450-mediated activation with a truncated azinomycin analogue | 2015 | MedChemComm | 6 | 187 - 191 | Vinader, Victoria; Sadiq, Maria; Sutherland, Mark H.; Huang, M.Y.; Loadman, Paul M.; Elsalem, Lina M.I.; Shnyder, Steven D.; Cui, H.J.; Afarinkia, Kamyar; Searcey, M.; Patterson, Laurence H.; Pors, Klaus | dx.doi.org/10.1039/c4md00411f | |||||
| Mathematical and computational models of drug transport in tumours | 2014 | Journal of the Royal Society Interface | 11 | 94 | Groh, C.M.; Hubbard, M.E.; Jones, P.F.; Loadman, Paul M.; Periasamy, Nagarajan; Sleeman, B.D.; Smye, S.W.; Twelves, Christopher J.; Phillips, Roger M. | doi.org/10.1098/rsif.2013.1173 | |||||
| In vitro 3D colon tumor penetrability of SRJ09, a new anti-cancer andrographolide analog | 2014 | Investigational New Drugs | 32 | 806 - 814 | Wong, C.C.; Periasamy, Nagarajan; Sagineedu, S.R.; Sidik, S.; Sumon, S.H.; Loadman, Paul M.; Phillips, Roger M.; Lajis, N.H.; Stanslas, J. | doi.org/10.1007/s10637-014-0105-6 | |||||
| Proteases in cancer drug delivery | 2016 | Advanced Drug Delivery Reviews | 97 | 144 - 145 | Vandooren, J.; Opdenakker, G.; Loadman, Paul M.; Edwards, D.R. | dx.doi.org/10.1016/j.addr.2015.12.020 | |||||
| Measurement of red blood cell eicosapentaenoic acid (EPA) levels in a randomised trial of EPA in patients with colorectal cancer liver metastases | 2016 | Prostaglandins Leukotrienes and Essential Fatty Acids | 115 | Watson, H.; Cockbain, A.J.; Spencer, Jade A.; Race, Amanda D.; Volpato, Milène; Loadman, Paul M.; Toogood, G.J.; Hull, M.A. | dx.doi.org/10.1016/j.plefa.2016.10.003 | ||||||
| Mucosal biomarkers of colorectal cancer risk do not increase at 6 months following sleeve gastrectomy, unlike gastric bypass | 2014 | Bmc Obesity | 22 | 202 - 210 | Kant, P.; Perry, S.L.; Dexter, S.P.; Race, Amanda D.; Loadman, Paul M. | doi.org/10.1002/oby.20493 | |||||
| Re-engineering of the Duocarmycin Structural Architecture Enables Bioprecursor Development Targeting CYP1A1 and CYP2W1 for Biological Activity | 2013 | Sheldrake, Helen M.; Travica, S.; Johansson, I.; Loadman, Paul M.; Sutherland, Mark H.; Elsalem, Lina M.I.; Illingworth, Nicola A.; Cresswell, Alexander J.; Reuillon, Tristan; Shnyder, Steven D.; Mkrtchian, S.; Searcey, M.; Ingelman-Sundberg, M.; Patterson, Laurence H.; Pors, Klaus | |||||||||
| Anticolorectal cancer activity of the omega-3 polyunsaturated fatty acid eicosapentaenoic acid | 2014 | Gut | 63 | 1760 - 1768 | Cockbain, A.J.; Volpato, Milène; Race, Amanda D.; Munarini, A.; Fazio, C.; Belluzzi, A.; Loadman, Paul M.; Toogood, G.J.; Hull, M.A. | doi.org/10.1136/gutjnl-2013-306445 | |||||
| Eicosapentaenoic acid free fatty acid prevents and suppresses colonic neoplasia in colitis-associated colorectal cancer acting on Notch signaling and gut microbiota | 2014 | International Journal of Cancer | 135 | 204 - 213 | Piazzi, G.; D'Argenio, G.; Prossomariti, A.; Lembo, V.; Mazzone, G.; Candela, M.; Biagi, E.; Brigidi, P.; Vitaglione, P.; Fogliano, V.; D'Angelo, L.; Fazio, C.; Munarini, A.; Belluzzi, A.; Ceccarelli, C.; Chieco, P.; Balbi, T.; Loadman, Paul M.; Hull, M.A.; Romano, M.; Bazzoli, F.; Ricciardiello, L. | doi.org/10.1002/ijc.28853 | |||||
| A randomised trial of the effect of omega-3 polyunsaturated fatty acid supplements on the human intestinal microbiota | 2018 | Gut | 67 | 1974 - 1983 | Watson, H.; Mitra, S.; Croden, F.C.; Taylor, M.; Wood, H.M.; Perry, S.L.; Spencer, Jade A.; Quirke, P.; Toogood, G.J.; Lawton, C.L.; Dye, L.; Loadman, Paul M.; Hull, M.A. | doi: 10.1136/gutjnl-2017-314968 | |||||
| Rationalized Computer-Aided Design of Matrix-Metalloprotease-Selective Prodrugs | 2017 | Journal of Medicinal Chemistry | 60 | 4496 - 4502 | Jain, M.; Harburn, J.J.; Gill, J.H.; Loadman, P.M.; Falconer, R.A.; Mooney, C.A.; Cobb, S.L.; Berry, David J. | 10.1021/acs.jmedchem.6b01472 | |||||
| A liquid chromatography-tandem mass spectrometry method to measure fatty acids in biological samples | 2017 | J Chromatography B | 1055 | 125 - 134 | Volpato, Milène; Spencer, Jade A.; Race, Amanda D.; Munarini, A.; Belluzzi, A.; Cockbain, A.; Hull, M.; Loadman, Paul M. | doi.org/10.1016/j.jchromb.2017.04.030 | |||||
| Drug delivery in a tumour cord model: a computational simulation | 2017 | Royal Society Open Science | 4 | 170014 | Hubbard, M.E.; Jove, M.; Loadman, Paul M.; Phillips, Roger M.; Twelves, Christopher J.; Smye, S.W. | doi.org/10.1098/rsos.170014 | |||||
| A novel theranostic strategy for MMP-14 expressing glioblastomas impacts survival | 2017 | Molecular Cancer Therapeutics | 16 | 1909 - 1921 | Mohanty, S.; Chen, Z.; Li, K.; Ribeiro Morais, G.; Klockow, J.; Yerneni, K.; Pasani, L.; Chin, F.T.; Mitra, S.; Cheshier, S.; Chang, E.; Gambhir, S.S.; Rao, J.; Loadman, P.M.; Falconer, R.A.; Daldrup-Link, H.E. | 10.1158/1535-7163.MCT-17-0022 | |||||
| Comparative Preclinical Pharmacokinetic and Metabolic Studies of the Combretastatin Prodrugs Combretastatin A4 Phosphate and A1 Phosphate | 2004 | Kirwan, Ian G.; Loadman, Paul M.; Swaine, David J.; Anthoney, Alan; Pettit, G.R.; Lippert III, J.W.; Shnyder, Steven D.; Cooper, Patricia A.; Bibby, Michael C. | |||||||||
| Membrane-type matrix metalloproteinases: expression, roles in metastatic prostate cancer progression and opportunities for drug targeting | 2017 | Journal of Cancer Metastasis and Treatment | 3 | 315 - 327 | Falconer, R.A.; Loadman, P.M. | 10.20517/2394-4722.2017.40 | |||||
| Structural properties governing drug-plasma protein binding determined by high-performance liquid chromatography method | 2018 | Journal of Pharmaceutical and Biomedical Analysis | 149 | 16 - 21 | Kamble, Sharad R.; Loadman, Paul M.; Abraham, M.H.; Liu, Xiangli | doi.org/10.1016/j.jpba.2017.10.022 | |||||
| A study of inter-individual variability in the Phase II metabolism of xenobiotics in human skin | 2018 | Toxicology Letters | 292 | 63 - 72 | Spriggs, S.; Cubberley, R.; Loadman, Paul M.; Sheffield, D.; Wierzbicki, Antonia | doi.org/10.1016/j.toxlet.2018.04.011 | |||||
| Membrane type matrix metalloproteinases (MMPs) show differential expression in non-small cell lung cancer (NSCLC) compared to normal lung: Correlation of MMP-14 mRNA expression and proteolytic activity | 2007 | European Journal of Cancer. Part A | 43 | 1764 - 1771 | Atkinson J.;Pennington C.;Martin S.;Anikin V.;Mearns A.;Loadman P.;Edwards D.;Gill J. | 0959-8049 | 10.1016/j.ejca.2007.05.009 | ||||
| Total synthesis of largazole and analogues: HDAC inhibition, antiproliferative activity and metabolic stability | 2011 | Bioorganic and Medicinal Chemistry | 19 | 3650 - 3658 | Benelkebir H.;Marie S.;Hayden A.;Lyle J.;Loadman P.;Crabb S.;Packham G.;Ganesan A. | 0968-0896 | 10.1016/j.bmc.2011.02.024 | ||||
| Detergent addition to tryptic digests and ion mobility separation prior to MS/MS improves peptide yield and protein identification for in situ proteomic investigation of frozen and formalin-fixed paraffin-embedded adenocarcinoma tissue sections | 2009 | Proteomics | 9 | 2750 - 2763 | Djidja M.;Francese S.;Loadman P.;Sutton C.;Scriven P.;Claude E.;Snel M.;Franck J.;Salzet M.;Clench M. | 1615-9853 | 10.1002/pmic.200800624 | ||||
| Combination chemotherapy with combretastatin A-4 phosphate and 5-fluorouracil in an experimental murine colon adenocarcinoma | 2000 | Anticancer Research | 20 | 229 - 233 | Grosios K.;Loadman P.;Swaine D.;Pettit G.;Bibby M. | 0250-7005 | |||||
| Examination of the distribution of the bioreductive drug AQ4N and its active metabolite AQ4 in solid tumours by imaging matrix-assisted laser desorption/ionisation mass spectrometry | 2007 | Rapid Communications In Mass Spectrometry | 21 | 1271 - 1276 | Atkinson S.;Loadman P.;Sutton C.;Patterson L.;Clench M. | 0951-4198 | 10.1002/rcm.2952 | ||||
| Detection of (NAD(P)H:Quinone oxidoreductase-1, EC 1.6.99.2) 609C-->T and 465C-->T polymorphisms in formalin-fixed, paraffin-embedded human tumour tissue using PCR-RFLP. | 2004 | International Journal of Oncology | 24 | 1005 - 1010 | Phillips R.;Basu S.;Brown J.;Flannigan G.;Loadman P.;Martin S.;Naylor B.;Puri R.;Shah T. | 1019-6439 | |||||
| Synthesis and biological evaluation of colchicine C-ring analogues tethered with aliphatic linkers suitable for prodrug derivatisation | 2012 | Bioorganic and Medicinal Chemistry Letters | 22 | 7693 - 7696 | Fournier-Dit-Chabert J.;Vinader V.;Santos A.;Redondo-Horcajo M.;Dreneau A.;Basak R.;Cosentino L.;Marston G.;Abdel-Rahman H.;Loadman P.;Shnyder S.;Díaz J.;Barasoain I.;Falconer R.;Pors K. | 0960-894X | 10.1016/j.bmcl.2012.09.104 | ||||
| Predicting tumor responses to mitomycin C on the basis of DT-diaphorase activity or drug metabolism by tumor homogenates: Implications for enzyme-directed bioreductive drug development | 2000 | Cancer Research | 60 | 6384 - 6390 | Phillips R.;Burger A.;Loadman P.;Jarrett C.;Swaine D.;Fiebig H. | 0008-5472 | |||||
| Effect of eicosapentaenoic acid on E-type prostaglandin synthesis and EP4 receptor signaling in human colorectal cancer cells | 2010 | Neoplasia | 12 | 618 - 627 | Hawcroft G.;Loadman P.;Belluzzi A.;Hull M. | 1522-8002 | 10.1593/neo.10388 | ||||
| Chromatographie analysis of polysialic acid released from neural adhesion molecule presented on glioma cell membranes | 2011 | Kuwait Journal of Science and Engineering | 38 | 107 - 130 | Al-Hasawi N.;Volapato M.;Loadman P. | 1024-8684 | |||||
| High-performance liquid chromatographic analysis of AQ4N, an alkylaminoanthraquinone N-oxide | 2000 | Journal of Chromatography B: Biomedical Sciences and Applications | 742 | 239 - 245 | Swaine D.;Loadman P.;Bibby M.;Graham M.;Patterson L. | 1387-2273 | 10.1016/S0378-4347(00)00160-2 | ||||
| 5,6-Dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: Phase I clinical and pharmacokinetic study | 2003 | British Journal of Cancer | 88 | 1160 - 1167 | Rustin G.;Bradley C.;Galbraith S.;Stratford M.;Loadman P.;Waller S.;Bellenger K.;Gumbrell L.;Folkes L.;Halbert G. | 0007-0920 | 10.1038/sj.bjc.6600885 | ||||
| A randomized controlled trial of eicosapentaenoic acid and/or aspirin for colorectal adenoma prevention during colonoscopic surveillance in the NHS Bowel Cancer Screening Programme (The seAFOod Polyp Prevention Trial): Study protocol for a randomized controlled trial | 2013 | Trials | 14 | Hull M.;Sandell A.;Montgomery A.;Logan R.;Clifford G.;Rees C.;Loadman P.;Whitham D. | 1745-6215 | 10.1186/1745-6215-14-237 | |||||
| Design, synthesis, and biophysical and biological evaluation of a series of pyrrolobenzodiazepine-poly(N-methylpyrrole) conjugates | 2006 | Journal of Medicinal Chemistry | 49 | 5442 - 5461 | Wells G.;Martin C.;Howard P.;Sands Z.;Laughton C.;Tiberghien A.;Woo C.;Masterson L.;Stephenson M.;Hartley J.;Jenkins T.;Shnyder S.;Loadman P.;Waring M.;Thurston D. | 0022-2623 | 10.1021/jm051199z | ||||
| In vivo activation of the hypoxia-targeted cytotoxin AQ4N in human tumor xenografts | 2009 | Molecular Cancer Therapeutics | 8 | 3266 - 3275 | Williams K.;Albertella M.;Fitzpatrick B.;Loadman P.;Shnyder S.;Chinje E.;Telfer B.;Dunk C.;Harris P.;Stratford I. | 1535-7163 | 10.1158/1535-7163.MCT-09-0396 | ||||
| Development of a novel tumor-targeted vascular disrupting agent activated by membrane-type matrix metalloproteinases | 2010 | Cancer Research | 70 | 6902 - 6912 | Atkinson J.;Falconer R.;Edwards D.;Pennington C.;Siller C.;Shnyder S.;Bibby M.;Patterson L.;Loadman P.;Gill J. | 0008-5472 | 10.1158/0008-5472.CAN-10-1440 | ||||
| FGFR1-induced Epithelial to mesenchymal transition through MAPK/PLCγ/COX-2-mediated mechanisms | 2012 | PLoS ONE | 7 | Tomlinson D.;Baxter E.;Loadman P.;Hull M.;Knowles M. | 1932-6203 | 10.1371/journal.pone.0038972 | |||||
| Pharmacological approach towards the development of indolequinone bioreductive drugs based on the clinically inactive agent EO9 | 2002 | British Journal of Pharmacology | 137 | 701 - 709 | Loadman P.;Bibby M.;Phillips R. | 0007-1188 | 10.1038/sj.bjp.0704916 | ||||
| Pharmacokinetics of PK1 and doxorubicin in experimental colon tumor models with differing responses to PK1 | 1999 | Clinical Cancer Research | 5 | 3682 - 3688 | Loadman P.;Bibby M.;Double J.;Al-Shakhaa W.;Duncan R. | 1078-0432 | |||||
| Hypoxia-selective targeting by the bioreductive prodrug AQ4N in patients with solid tumors: Results of a phase I study | 2008 | Clinical Cancer Research | 14 | 1096 - 1104 | Albertella M.;Loadman P.;Jones P.;Phillips R.;Rampling R.;Burnet N.;Alcock C.;Anthoney A.;Vjaters E.;Dunk C.;Harris P.;Wong A.;Lalani A.;Twelves C. | 1078-0432 | 10.1158/1078-0432.CCR-07-4020 | ||||
| A preclinical pharmacokinetic study of the bioreductive drug AQ4N | 2001 | Drug Metabolism and Disposition | 29 | 422 - 426 | Loadman P.;Swaine D.;Bibby M.;Welham K.;Patterson L. | 0090-9556 | |||||
| Expression of matrix metalloproteinase-10 in human bladder transitional cell carcinoma | 2005 | Urology | 65 | 815 - 820 | Seargent J.;Loadman P.;Martin S.;Naylor B.;Bibby M.;Gill J. | 0090-4295 | 10.1016/j.urology.2004.11.016 | ||||
| Formation of DNA interstrand cross-links as a marker of Mitomycin C bioreductive activation and chemosensitivity | 2005 | European Journal of Cancer. Part A | 41 | 1331 - 1338 | Volpato M.;Seargent J.;Loadman P.;Phillips R. | 0959-8049 | 10.1016/j.ejca.2005.03.014 | ||||
| The omega-3 polyunsaturated fatty acid eicosapentaenoic acid inhibits mouse MC-26 colorectal cancer cell liver metastasis via inhibition of PGE |
2012 | British Journal of Pharmacology | 166 | 1724 - 1737 | Hawcroft G.;Volpato M.;Marston G.;Ingram N.;Perry S.;Cockbain A.;Race A.;Munarini A.;Belluzzi A.;Loadman P.;Coletta P.;Hull M. | 0007-1188 | 10.1111/j.1476-5381.2012.01882.x | ||||
| Comet assay and flow cytometry analysis of DNA repair in normal and cancer cells treated with known mutagens with different mechanisms of action. | 2003 | Teratogenesis Carcinogenesis and Mutagenesis | Suppl 2 | 13 - 29 | Suggitt M.;Fearnley J.;Swaine D.;Volpato M.;Phillips R.;Bibby M.;Loadman P.;Anderson D. | 0270-3211 | |||||
| Pharmacological properties of a new aziridinylbenzoquinone, RH1 (2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone), in mice | 2000 | Biochemical Pharmacology | 59 | 831 - 837 | Loadman P.;Phillips R.;Lim L.;Bibby M. | 0006-2952 | 10.1016/S0006-2952(99)00391-3 | ||||
| Synthesis and biological evaluation of colchicine B-ring analogues tethered with halogenated benzyl moieties | 2012 | Journal of Medicinal Chemistry | 55 | 11062 - 11066 | Cosentino L.;Redondo-Horcajo M.;Zhao Y.;Santos A.;Chowdury K.;Vinader V.;Abdallah Q.;Abdel-Rahman H.;Fournier-Dit-Chabert J.;Shnyder S.;Loadman P.;Fang W.;Díaz J.;Barasoain I.;Burns P.;Pors K. | 0022-2623 | 10.1021/jm301151t | ||||
| In vivo metabolism of the antitumor imidazoacridinone C1311 in the mouse and in vitro comparison with humans | 1999 | Drug Metabolism and Disposition | 27 | 240 - 245 | Calabrese C.;Loadman P.;Lim L.;Bibby M.;Double J.;Brown J.;Lamb J. | 0090-9556 | |||||
| The use of pharmacokinetic and pharmacodynamic end points to determine the dose of AQ4N, a novel hypoxic cell cytotoxin, given with fractionated radiotherapy in a phase I study | 2007 | Annals of Oncology | 18 | 1098 - 1103 | Steward W.;Middleton M.;Benghiat A.;Loadman P.;Hayward C.;Waller S.;Ford S.;Halbert G.;Patterson L.;Talbot D. | 0923-7534 | 10.1093/annonc/mdm120 | ||||
| Anti-colorectal cancer activity of an organometallic osmium arene azopyridine complex | 2011 | MedChemComm | 2 | 666 - 668 | Shnyder S.;Fu Y.;Habtemariam A.;Van Rijt S.;Cooper P.;Loadman P.;Sadler P. | 2040-2503 | 10.1039/c1md00075f | ||||
| Eicosapentaenoic acid and aspirin, alone and in combination, for the prevention of colorectal adenomas (seAFOod Polyp Prevention trial): a multicentre, randomised, double-blind, placebo-controlled, 2 × 2 factorial trial | 2018 | Lancet | 392 | 2583 - 2594 | Hull, M.A.; Sprange, K.; Hepburn, T.; Tan, W.; Shafayat, A.; Rees, C.J.; Clifford, G.; Logan, R.F.; Loadman, Paul M.; Williams, E.A.; Whitham, D.; Montgomery, A.A. | doi.org/10.1016/S0140-6736(18)31775-6 | |||||
| Extraction of the synthetic lytic peptide, cecropin B, from biological fluid and analysis using reversed-phase high-performance liquid chromatography | 1995 | Journal of Chromatography - Biomedical Applications | 672 | 225 - 231 | Moore A.;Loadman P.;Devine D.;Bibby M. | 0378-4347 | 10.1016/0378-4347(95)00233-9 | ||||
| Inactivation of apaziquone by haematuria: implications for the design of phase III clinical trials against non-muscle invasive bladder cancer | 2019 | Cancer Chemotherapy and Pharmacology | 83 | Roger M. Phillips, Paul M. Loadman, Guru Reddy | 10.1007/s00280-019-03812-7 | ||||||
| Gas chromatographic analysis of triethylenethiophosphoramide and triethylenephosphoramide in biological specimens | 1985 | Journal of Chromatography - Biomedical Applications | 338 | 335 - 345 | McDermott B.;Double J.;Bibby M.;Wilman D.;Loadman P.;Turner R. | 0378-4347 | 10.1016/0378-4347(85)80104-3 | ||||
| Influence of the tissue distribution of ThioTEPA and its metabolite, TEPA, on the response of murine colon tumours | 1987 | Cancer Chemotherapy and Pharmacology | 20 | 203 - 206 | Bibby M.;McDermott B.;Double J.;Phillips R.;Loadman P.;Burgess L. | 0344-5704 | 10.1007/BF00570485 | ||||
| Analysis of the imidazoacridinone C1311 by high-performance liquid chromatography | 1997 | JOURNAL OF CHROMATOGRAPHY B-BIOMEDICAL APPLICATIONS | 690 | 275 - 281 | Calabrese C.;Loadman P. | 1572-6495 | 10.1016/S0378-4347(96)00387-8 | ||||
| Factors involved in the anti-cancer activity of the investigational agents LM985 (Flavone acetic acid ester) and LM975 (flavone acetic acid) | 1987 | British Journal of Cancer | 55 | 159 - 163 | Bibby M.;Double J.;Phillips R.;Loadman P. | 0007-0920 | 10.1038/bjc.1987.32 | ||||
| Potentiation of EO9 anti-tumour activity by hydralazine | 1993 | European Journal of Cancer. Part A | 29 | 1033 - 1035 | Bibby M.;Sleigh N.;Loadman P.;Double J. | 0959-8049 | 10.1016/S0959-8049(05)80218-7 | ||||
| Pre-cinical evaluation of a novel chloroethylating agent, clomesone | 1993 | British Journal of Cancer | 67 | 441 - 446 | Matthew A.;Phillips R.;Loadman P.;Bibby M. | 0007-0920 | 10.1038/bjc.1993.85 | ||||
| Reduction of tumor blood flow by flavone acetic acid: A possible component of therapy | 1989 | Journal of the National Cancer Institute | 81 | 216 - 220 | Bibby M.;Double J.;Loadman P.;Duke C. | 0027-8874 | 10.1093/jnci/81.3.216 | ||||
| The relationship between the in vitro chemosensitivity of tumor cells and tumor response in vivo in an experimental tumor model | 1991 | International Journal of Cell Cloning | 9 | 144 - 154 | Phillips R.;Bibby M.;Double J.;Loadman P. | 0737-1454 | 10.1002/stem.5530090205 | ||||
| Cellular uptake and efflux of palbociclib in vitro in single cell and spheroid models. | 2019 | Journal of Pharmacology and Experimental Therapeutics | 371 | Jove M;Spencer JA;Hubbard ME;Holden EC;O'Dea RD;Brook BS;Phillips RM;Smye SW;Loadman P;Twelves CJ; | 1521-0103 | 10.1124/jpet.119.256693 | |||||
| Recent advances in the analysis of polysialic acid from complex biological systems | 2019 | Carbohydrate Polymers | 16 | Xiaoxiao Guo, Sara M. Elkashef, Mark Sutherland, Paul M. Loadman and Robert A. Falconer | 10.1016/j.carbpol.2019.115145 | ||||||
| Precision pharmacology: Mass spectrometry imaging and pharmacokinetic drug resistance | 2019 | Critical Reviews in Oncology/Hematology | 141 | 153 - 162 | Jove, M.; Spencer, Jade A.; Clench, M.; Loadman, Paul M.; Twelves, C. | DOI.org/10.1016/j.critrevonc.2019.06.008 | |||||
| Precision pharmacology: Mass spectrometry imaging and pharmacokinetic drug resistance | 2019 | Critical Reviews in Oncology/Hematology | 141 | 153 - 162 | Jove, M.; Spencer, Jade A.; Clench, M.; Loadman, Paul M.; Twelves, C. | DOI.org/10.1016/j.critrevonc.2019.06.008 | |||||
| Precision pharmacology: Mass spectrometry imaging and pharmacokinetic drug resistance | 2019 | Critical Reviews in Oncology/Hematology | 141 | 153 - 162 | Jove, M.; Spencer, Jade A.; Clench, M.; Loadman, Paul M.; Twelves, C. | DOI.org/10.1016/j.critrevonc.2019.06.008 | |||||
| Precision pharmacology: Mass spectrometry imaging and pharmacokinetic drug resistance | 2019 | Critical Reviews in Oncology/Hematology | 141 | 153 - 162 | Jove, M.; Spencer, Jade A.; Clench, M.; Loadman, Paul M.; Twelves, C. | DOI.org/10.1016/j.critrevonc.2019.06.008 | |||||
| Precision pharmacology: Mass spectrometry imaging and pharmacokinetic drug resistance | 2019 | Critical Reviews in Oncology/Hematology | 141 | 153 - 162 | Jove, M.; Spencer, Jade A.; Clench, M.; Loadman, Paul M.; Twelves, C. | DOI.org/10.1016/j.critrevonc.2019.06.008 | |||||
| Precision pharmacology: Mass spectrometry imaging and pharmacokinetic drug resistance | 2019 | Critical Reviews in Oncology/Hematology | 141 | 153 - 162 | Jove, M.; Spencer, Jade A.; Clench, M.; Loadman, Paul M.; Twelves, C. | DOI.org/10.1016/j.critrevonc.2019.06.008 | |||||
| Precision pharmacology: Mass spectrometry imaging and pharmacokinetic drug resistance | 2019 | Critical Reviews in Oncology/Hematology | 141 | 153 - 162 | Jove, M.; Spencer, Jade A.; Clench, M.; Loadman, Paul M.; Twelves, C. | DOI.org/10.1016/j.critrevonc.2019.06.008 | |||||
| Precision pharmacology: Mass spectrometry imaging and pharmacokinetic drug resistance | 2019 | Critical Reviews in Oncology/Hematology | 141 | 153 - 162 | Jove, M.; Spencer, Jade A.; Clench, M.; Loadman, Paul M.; Twelves, C. | DOI.org/10.1016/j.critrevonc.2019.06.008 | |||||
| Precision pharmacology: Mass spectrometry imaging and pharmacokinetic drug resistance | 2019 | Critical Reviews in Oncology/Hematology | 141 | 153 - 162 | Jove, M.; Spencer, Jade A.; Clench, M.; Loadman, Paul M.; Twelves, C. | DOI.org/10.1016/j.critrevonc.2019.06.008 | |||||
| Precision pharmacology: Mass spectrometry imaging and pharmacokinetic drug resistance | 2019 | Critical Reviews in Oncology/Hematology | 141 | 153 - 162 | Jove, M.; Spencer, Jade A.; Clench, M.; Loadman, Paul M.; Twelves, C. | DOI.org/10.1016/j.critrevonc.2019.06.008 | |||||
| Precision pharmacology: Mass spectrometry imaging and pharmacokinetic drug resistance | 2019 | Critical Reviews in Oncology/Hematology | 141 | 153 - 162 | Jove, M.; Spencer, Jade A.; Clench, M.; Loadman, Paul M.; Twelves, C. | DOI.org/10.1016/j.critrevonc.2019.06.008 | |||||
| Precision pharmacology: Mass spectrometry imaging and pharmacokinetic drug resistance | 2019 | Critical Reviews in Oncology/Hematology | 141 | 153 - 162 | Jove, M.; Spencer, Jade A.; Clench, M.; Loadman, Paul M.; Twelves, C. | DOI.org/10.1016/j.critrevonc.2019.06.008 | |||||
| Precision pharmacology: Mass spectrometry imaging and pharmacokinetic drug resistance | 2019 | Critical Reviews in Oncology/Hematology | 141 | 153 - 162 | Jove, M.; Spencer, Jade A.; Clench, M.; Loadman, Paul M.; Twelves, C. | DOI.org/10.1016/j.critrevonc.2019.06.008 | |||||
| Precision pharmacology: Mass spectrometry imaging and pharmacokinetic drug resistance | 2019 | Critical Reviews in Oncology/Hematology | 141 | 153 - 162 | Jove, M.; Spencer, Jade A.; Clench, M.; Loadman, Paul M.; Twelves, C. | DOI.org/10.1016/j.critrevonc.2019.06.008 | |||||
| Precision pharmacology: Mass spectrometry imaging and pharmacokinetic drug resistance | 2019 | Critical Reviews in Oncology/Hematology | 141 | 153 - 162 | Jove, M.; Spencer, Jade A.; Clench, M.; Loadman, Paul M.; Twelves, C. | DOI.org/10.1016/j.critrevonc.2019.06.008 | |||||
| Precision pharmacology: Mass spectrometry imaging and pharmacokinetic drug resistance | 2019 | Critical Reviews in Oncology/Hematology | 141 | 153 - 162 | Jove, M.; Spencer, Jade A.; Clench, M.; Loadman, Paul M.; Twelves, C. | DOI.org/10.1016/j.critrevonc.2019.06.008 | |||||
| Theranostic nanoparticles enhance the response of glioblastomas to radiation | 2019 | Nanotheranostics | 3 | 299 - 310 | Wu, W.; Klockow, J.L.; Mohanty, S.; Ku, K.S.; Aghighi, M.; Melemenidis, S.; Chen, Z.; Li, K.; Ribeiro Morais, Goreti; Zhao, N.; Schlegel, J.; Graves, E.E.; Rao, J.; Loadman, Paul M.; Falconer, R.A.; Mukherjee, S.; Chin, F.T.; Daldrup-Link, H.E. | 10.7150/ntno.35342 | |||||
| An efficient assay for identification and quantitative evaluation of potential polysialyltransferase inhibitors. | 2020 | ANALYST (PRINT) | 145 | 4512 - 4521 | Guo X; Malcolm J.R.; Ali M.M.; Ribeiro Morais G; Shnyder S.D.; Loadman P.M.; Patterson L.H.; Falconer R.A. | 1364-5528 | 10.1039/d0an00721h | ||||
| Ultrasound-triggered therapeutic microbubbles enhance the efficacy of cytotoxic drugs by increasing circulation and tumour drug accumulation and limiting bioavailability and toxicity in normal tissues | 2020 | Theranostics | 10 | Nicola Ingram1*, Laura E. McVeigh1*, Radwa H. Abou-Saleh2,3, Juliana Maynard4, Sally A. Peyman2, James R. McLaughlan5, Michael Fairclough6, Gemma Marston1, Elizabeth M.A. Valleley 1, Jorge L. Jimenez-Macias1, Antonia Charalambous1, William Townley4, Malcolm Haddrick4, Antonia Wierzbicki7, Alexander Wright1, Milène Volpato1, Peter B. Simpson4, Darren E. Treanor1, Neil H. Thomson8, Paul M. Loadman7, Richard J. Bushby2,9, Benjamin R.G. Johnson2, Pamela F. Jones1, Tony Evans1, Steven Freear5, Alexander F. Markham1, Stephen D. Evans2,*, P. Louise Coletta1,* | ISSN: 1838-7640 | Ivy Spring | DOI: 10.7150/thno.49670 | ||||
| Luminal bioavailability in the distal small intestine and changes to the ileal microbiome after oral administration of omega-3 polyunsaturated fatty acids | 2021 | Journal of Nutrition | may24 | Gael Nana, Henry Watson, Suparna Mitra, Caroline Young, Henry M Wood, Sarah L Perry, Amanda D Race, Philip Quirke, Giles J Toogood, Paul M Loadman, Mark A Hull | doi: 10.1093/jn/nxab113 | ||||||
| Targeted microbubbles carrying lipid-oil-nanodroplets for ultrasound-triggered delivery of the hydrophobic drug, Combretastatin A4. | 2021 | Nanomedicine: Nanotechnology, Biology, and Medicine | Charalambous A;Mico V;McVeigh LE;Marston G;Ingram N;Volpato M;Peyman SA;McLaughlan JR;Wierzbicki A;Loadman P;Bushby RJ;Markham AF;Evans SD;Coletta PL; | 1549-9642 | 10.1016/j.nano.2021.102401 | ||||||
| Probing cytochrome P450 (CYP) bioactivation with chloromethylindoline bioprecursors derived from the duocarmycin family of compounds. | 2021 | Bioorganic and Medicinal Chemistry | 40 | Ortuzar N;Karu K;Presa D;Morais GR;Sheldrake HM;Shnyder SD;Barnieh FM;Loadman PM;Patterson LH;Pors K;Searcey M; | 1464-3391 | 10.1016/j.bmc.2021.116167 | |||||
| How can the potential of the duocarmycins be unlocked for cancer therapy? | 2021 | Drug Discovery Today | 26 | Jukes Z;Morais GR;Loadman PM;Pors K; | 1878-5832 | 10.1016/j.drudis.2020.11.020 | |||||
| An assay for quantitative analysis of polysialic acid expression in cancer cells | 2021 | Carbohydrate Polymers | 259 | Guo, X.; Elkashef, S.M.; Patel, A.; Ribeiro Morais, G.; Shnyder S.D.; Loadman, P.M.; Patterson, L.H.; Falconer, R.A. | 10.1016/j.carbpol.2021.117741 | ||||||
| Progress towards a clinically-successful ATR inhibitor for cancer therapy | 2021 | Current Research in Pharmacology and Drug Discovery | 2 | 100017 | Barnieh, F.M.; Loadman, P.M.; Falconer, R.A. | 10.1016/j.crphar.2021.100017 | |||||
| The role of MT1-MMP in the progression and metastasis of osteosarcoma | 2022 | Journal of Cancer Metastasis and Treatment | 9 | Spencer, H.L.M.; Shnyder, S.D.; Loadman, P.M.; Falconer, R.A. | DOI:10.20517/2394-4722.2021.174 | ||||||
| Cytochrome P450 Binding and Bioactivation of Tumor-targeted Duocarmycin Agents. | 2021 | Drug Metabolism And Disposition: The Biological Fate Of Chemicals | Bart AG;Morais G;Vangala VR;Loadman PM;Pors K;Scott EE; | 1521-009X | 10.1124/dmd.121.000642 | ||||||
| Cytochrome P450 isoforms 1A1, 1B1 AND 2W1 as targets for therapeutic intervention in head and neck cancer. | 2021 | Scientific Reports | 11 | Presa D;Khurram SA;Zubir AZA;Smarakan S;Cooper PA;Morais GR;Sadiq M;Sutherland M;Loadman PM;McCaul J;Shnyder SD;Patterson LH;Pors K; | 2045-2322 | 10.1038/s41598-021-98217-z | |||||
| Is tumour-expressed aminopeptidase N (APN/CD13) structurally and functionally unique? | 2021 | Biochimica et Biophysica Acta - Reviews on Cancer | 1876 | Barnieh FM;Loadman PM;Falconer RA; | 1879-2561 | 10.1016/j.bbcan.2021.188641 | |||||
| Targeted delivery of a colchicine analogue provides synergy with ATR inhibition in cancer cells. | 2022 | Biochemical Pharmacology | Barnieh FM;Ribeiro Morais G;Garland H;Loadman PM;Falconer RA; | 1873-2968 | 10.1016/j.bcp.2022.115095 | ||||||
| Intermittent PI3Kδ inhibition sustains anti-tumour immunity and curbs irAEs. | 2022 | Nature | 605 | Eschweiler S;Ramírez-Suástegui C;Li Y;King E;Chudley L;Thomas J;Wood O;von Witzleben A;Jeffrey D;McCann K;Simon H;Mondal M;Wang A;Dicker M;Lopez-Guadamillas E;Chou TF;Dobbs NA;Essame L;Acton G;Kelly F;Halbert G;Sacco JJ;Schache AG;Shaw R;McCaul JA;Paterson C;Davies JH;Brennan PA;Singh RP;Loadman PM;Wilson W;Hackshaw A;Seumois G;Okkenhaug K;Thomas GJ;Jones TM;Ay F;Friberg G;Kronenberg M;Vanhaesebroeck B;Vijayanand P;Ottensmeier CH; | 1476-4687 | 10.1038/s41586-022-04685-2 |
Reviews
| Title | Year | Publication name | Journal | Volume | Pages | Authors | Editors | ISSN | Publisher | DOI | Location |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Separation methods for anthraquinone related anti-cancer drugs | 2001 | Journal of Chromatography B: Biomedical Sciences and Applications | 764 | 193 - 206 | Loadman P.;Calabrese C. | 1387-2273 | 10.1016/S0378-4347(01)00281-X | ||||
| Use of matrix-assisted laser desorption/ionisation mass spectrometry in cancer research | 2011 | Journal of Pharmacological and Toxicological Methods | 64 | 197 - 206 | Bateson H.;Saleem S.;Loadman P.;Sutton C. | 1056-8719 | 10.1016/j.vascn.2011.04.003 | ||||
| Current advances in the inhibition of the auto-regulatory interaction between the p53 tumour suppressor protein and MDM2 protein | 2001 | Expert Opinion on Therapeutic Patents | 11 | 1825 - 1835 | Picksley S.;Dart D.;Mansoor M.;Loadman P. | 1354-3776 | 10.1517/13543776.11.12.1825 | ||||
| Proteases in cancer drug delivery | 2016 | Advanced Drug Delivery Reviews | 97 | 144 - 155 | Vandooren J.;Opdenakker G.;Loadman P.;Edwards D. | 0169-409X | 10.1016/j.addr.2015.12.020 | ||||
| Precision pharmacology: Mass spectrometry imaging and pharmacokinetic drug resistance | 2019 | Critical Reviews in Oncology/Hematology | 141 | 153 - 162 | Jove M.;Spencer J.;Clench M.;Loadman P.;Twelves C. | 1040-8428 | 10.1016/j.critrevonc.2019.06.008 |